CVRX Q3 2025 Earnings Call Summary

Revenue: $14.7 million for Q3 2025, a 10% increase from $13.4 million in Q3 2024.
U.S. Revenue: $13.5 million, up 10% year-over-year.
Units Sold: 420 in the U.S., compared to 394 in Q3 2024.
Gross Profit: $12.8 million, a 15% increase, with gross margin rising to 87% from 83%.
Net Loss: $12.9 million or $0.49 per share, slightly improved from a loss of $13.1 million or $0.57 per share in Q3 2024.
Cash Position: $85.1 million as of September 30, 2025.
Operating Expenses: Increased to $21.9 million, primarily due to consulting and travel expenses.

Sales Organization: The transformation of the sales force is progressing, with new hires becoming productive. The company added 10 net new implanting centers in Q3.
Therapy Adoption: Over 20% of active centers performed three or more implants in Q3, with top sites exceeding ten implants per quarter.
Reimbursement Developments: CMS proposed maintaining Barostim in new technology APC 1580, with a Category I CPT code effective January 1, 2026, which is expected to enhance patient access and reimbursement predictability.
Clinical Evidence: Positive outcomes from independent studies are being reported, and discussions with the FDA regarding a new randomized controlled trial (RCT) are ongoing.

2025 Revenue Guidance: Expected to be between $55.6 million and $56.6 million, slightly narrowed from previous guidance.
Q4 Revenue Expectation: Projected between $15 million and $16 million.
2026 Growth Outlook: Anticipated mid-teens growth rate, with potential for acceleration due to improved sales force productivity and reimbursement changes.

Sales Growth: Q4 guidance indicates a potential slowdown, with only 6% sequential growth expected, which may reflect conservatism in projections despite positive trends.
Operating Expenses: Increased R&D expenses (up 26%) and interest expenses due to higher borrowings could pressure profitability.
Sales Force Productivity: While new reps are becoming productive, full productivity is still not realized, and the company acknowledges ongoing challenges in ramping up new hires effectively.

Guidance Clarification: Management indicated that while Q3 performance was strong, they prefer to be conservative in guidance to ensure they do not overestimate future growth.
Sales Force Development: The company is focused on enhancing training and support for new hires to expedite their productivity ramp-up, with an emphasis on selecting high-potential accounts.
RCT and Market Expansion: The planned RCT could significantly expand the addressable market for Barostim therapy, with enrollment expected to start in the first half of 2026 pending FDA approval.
Reimbursement Changes: The transition to a Category I code is expected to reduce prior authorization friction, potentially leading to improved approval rates for procedures.

This summary encapsulates CVRx's performance and strategic direction while highlighting both opportunities and challenges as they move forward.

CVRX — CVRx, Inc.